CClinicalTrials.gg
TerminatedNCT05445869Updated Apr 18, 2024

Severe OSA Study (SOS)

An interventional study of ProSomnus® EVO Sleep and Snore Device in Obstructive Sleep Apnea and Sleep Apnea, sponsored by ProSomnus Sleep Technologies. Terminated at 5 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-18.

Sponsored by ProSomnus Sleep Technologies · Not applicable, Interventional, and Treatment

Why this study was terminated
Study terminated by Sponsor.

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 7 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is a prospective, multi-center, single-arm, open-label study evaluating the safety and effectiveness of therapy with the ProSomnus EVO Sleep and Snore Device in individuals with severe obstructive sleep apnea.

Read the detailed description

This study is a prospective, multi-center, single-arm, open-label study evaluating the safety and effectiveness of therapy with the ProSomnus EVO Sleep and Snore Device in individuals with severe obstructive sleep apnea (OSA). Study participants will receive a custom ProSomnus EVO Sleep and Snore device and then be tested using a Type II home sleep apnea test (HSAT) to determine if they have achieved apnea-hypopnea index (AHI) \< 15 h-1 with the device in place. Home sleep apnea testing will be conducted at predetermined timepoints rather than based on subjective measures such as symptom alleviation. After completing a set device advancement and testing protocol, study participants will complete a final HSAT six months after therapy initiation. This value will be used to determine the therapeutic success rate of the appliance. Safety evaluations will be conducted at each study visit that takes place after therapy initiation. These evaluations, along with dental examinations and adverse event reports, will be used to determine if the safety endpoint is met. Participants will continue to be followed for an additional six months after collection of data for the primary endpoints.

02

Conditions studied

  • Obstructive Sleep Apnea
  • Sleep Apnea

Keywords

  • oral appliance
  • mandibular advancement device
03

In context

Apnea

1,422 studies on the registry are indexed under Apnea; 159 are open to participants now.

This study's enrollment of 35 is below the median of 50 across 965 interventional studies indexed under Apnea.

Browse Apnea studies →

Lead sponsor

ProSomnus Sleep Technologies is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Provision of signed and dated informed consent form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, of any race, aged 18-80 years (inclusive)
  4. Diagnosed with uncomplicated severe OSA (i.e., AHI > 30 h-1); where uncomplicated is defined by the absence of:

    1. Conditions that place the patient at increased risk of non-obstructive sleep-disordered breathing (e.g., central sleep apnea, hypoventilation, and sleep-related hypoxemia). Examples of such conditions include significant cardiopulmonary disease, potential respiratory muscles weakness due to neuromuscular conditions, history of stroke, and chronic opiate medication use.
    2. Concern for significant non-respiratory sleep disorder(s) that require evaluation (e.g., disorders of central hypersomnolence, parasomnias, sleep-related movement disorders) or interfere with accuracy of HSAT (e.g., severe insomnia).
    3. Environmental or personal factors that preclude the adequate acquisition and interpretation of data from HSAT.
  5. Body mass index (BMI) \< 40 kg/m2
  6. Neck circumference \< 50 cm
  7. Absence of severe oxyhemoglobin desaturation during sleep, indicated by mean nocturnal SpO2 > 87%
  8. Mandibular range of motion > 5 mm in protrusive direction
  9. Adequate dentition, as determined by the site dentist

Exclusion criteria

Exclusion Criteria:

  1. Inability to breathe through the nose comfortably
  2. Presence of > 25% CSA
  3. Presence of positional obstructive sleep apnea per Cartwright's definition32
  4. History of surgery intended to alter anatomy for the correction of OSA, such as uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), or tongue/hyoid suspension. History of surgery intended to restore normal anatomy, such as tonsillectomy, adenoidectomy, septoplasty, or polypectomy, is permitted
  5. Presence of hypoglossal nerve stimulation device
  6. Use of CPAP or OAT within the two weeks prior to the screening HSAT
  7. History of OAT that has been demonstrated to provide effective therapy within the two years prior to the screening HSAT
  8. Anticipated change in medical therapy during the study protocol that could alter OSA severity (e.g., weight loss surgeries; UPPP, MMA, tongue/hyoid suspension)
  9. Loose teeth or advanced periodontal disease
  10. History of temporomandibular joint disorder
  11. Resistant hypertension, defined as inadequately controlled blood pressure despite therapy with ≥ 3 oral hypertensive agents
  12. Presence of congestive heart failure, recurrent atrial fibrillation, or coronary artery disease
  13. Presence of neuromuscular diseases, hypoventilation disorders, or cerebrovascular disease
  14. Presence of pulmonary disease resulting in significant desaturation, e.g., severe chronic obstructive pulmonary disease, interstitial lung disease (SaO2 nadir of 87%), or pulmonary hypertension
  15. History of cerebrovascular incident within the last 12 months
  16. Use of pacemaker or other life supporting device
  17. Anticipated change in body weight > 5% during the study period
  18. Participation in other studies that could interfere with the study protocol
  19. Pregnancy or lactation
  20. In the opinion of the investigator, unsuitable for inclusion in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    EVO Sleep and Snore Device

    Participants will be provided with a custom EVO Sleep and Snore Device

    Device: ProSomnus® EVO Sleep and Snore Device

Interventions

  • DeviceProSomnus® EVO Sleep and Snore Device

    The ProSomnus® EVO Sleep and Snore Device is an intraoral device for snoring and obstructive sleep apnea. It works by repositioning the mandible during sleep, thereby improving the flow of air through the patient's pharyngeal space. The ProSomnus® EVO Sleep consists of maxillary and mandibular device arches that are CAD/CAM designed with twin-mated posts and digitally milled to be patient-specific according to physician prescription. Prescribed advancements can be achieved by simply removing the current upper or lower device arch and inserting the next upper or lower device arch in the mandibular advancement series. The device does not have any adjustment mechanisms to modify or maintain the mandibular position such as pistons, screws, straps, or repositioning elastics. The device is supplied nonsterile.

06

What researchers measure

Primary outcomes

  1. Efficacy (apnea-hypopnea index)

    The AHI co-primary effectiveness endpoint is to demonstrate a responder rate significantly greater than 50%; responders will be defined as individuals who achieve an AHI \< 15 h-1 with the EVO Sleep and Snore Device 6 months after initiation of the therapy.

    Time frame: 6 months

  2. Efficacy (oxygen desaturation index)

    The ODI co-primary effectiveness endpoint is to demonstrate a responder rate significantly greater than 50%; responders will be defined as individuals who achieve decrease in ODI from baseline of 25% or more with the EVO Sleep and Snore Device 6 months after initiation of the therapy.

    Time frame: 6 months

  3. Evaluation of safety (adverse events, dental examinations, safety examinations)

    The primary safety endpoint is to demonstrate an acceptable safety profile of the EVO Sleep and Snore Device, determined through assessment of all reported adverse events, dental examinations, and safety evaluations. There will be no formal statistical analysis.

    Time frame: 6 months

Secondary outcomes

  1. Epworth Sleepiness Scale

    The secondary endpoint is to demonstrate that the minimum clinically important difference (MCID) of -2 on the Epworth Sleepiness Scale (ESS) is achieved in participants with moderate to excessive daytime sleepiness (defined as ESS \> 12). The Epworth Sleepiness Scale is a scale that ranges from 0 (no daytime sleepiness) to 18 (excessive daytime sleepiness).

    Time frame: 6 months

07

Study locations

5 sites
  • Stanford Sleep Medicine Clinic
    Redwood City, California 94063, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Advanced ENT Physicians and Surgeons of CNY
    Fayetteville, New York 13066, United States
  • Mount Sinai Integrative Sleep Center
    New York, New York 10010, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05445869
Lead sponsor
ProSomnus Sleep Technologies
Responsible party
Sponsor
First posted
Jul 6, 2022
Start date
Sep 12, 2022
Primary completion
Feb 15, 2024
Completion
Feb 15, 2024
Last update
Apr 18, 2024

Study contacts

Erin Mosca, PhD
study director · ProSomnus Sleep Technologies

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion